In Vitro Effects of Preservative-Free Tafluprost and Preserved Latanoprost, Travoprost, and Bimatoprost in a Conjunctival Epithelial Cell Line

REFERENCES

• Becquet F, Goldschild M, Moldovan M S, Ettaiche M, Gastaud P, Baudouin C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res 1998; 17: 419–425
   PubMed Web of Science ®Google Scholar
• De Saint Jean M, Brignole F, Bringuier A F, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40: 619–630
   PubMed Web of Science ®Google Scholar
• Debbasch C, Brignole F, Pisella P J, Warnet J M, Rat P, Baudouin C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42: 642–652
   PubMed Web of Science ®Google Scholar
• Debbasch C, Pisella P J, De Saint Jean M, Rat P, Warnet J M, Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42: 2525–2533
   PubMed Web of Science ®Google Scholar
• Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996; 7: 80–86
   PubMedGoogle Scholar
• Herreras J M, Pastor J C, Calonge M, Asensio V M. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992; 99: 1082–1088
   PubMed Web of Science ®Google Scholar
• Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004; 111: 2186–2192
   PubMed Web of Science ®Google Scholar
• Hamard P, Blondin C, Debbasch C, Warnet J M, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol 2003; 241: 1037–1043
   PubMed Web of Science ®Google Scholar
• Yalvaç I S, Gedikoğlu G, Karagöz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995; 73: 246–248
   PubMedGoogle Scholar
• Yee R W. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: A review. Curr Opin Ophthalmol 2007; 18: 134–139
   PubMed Web of Science ®Google Scholar
• Baudouin C. Mechanisms of failure in glaucoma filtering surgery: A consequence of antiglaucomatous drugs?. Int J Clin Pharmacol Res. 1996; 16: 29–41
   PubMedGoogle Scholar
• Broadway D C, Grierson I, O'Brien C, Hitchings R A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994; 112: 1446–1454
   PubMed Web of Science ®Google Scholar
• Guenoun J M, Baudouin C, Rat P, Pauly A, Warnet J M, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46: 4594–4599
   PubMed Web of Science ®Google Scholar
• Guenoun J M, Baudouin C, Rat P, Pauly A, Warnet J M, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46: 2444–2450
   PubMed Web of Science ®Google Scholar
• Buron N, Micheau O, Cathelin S, Lafontaine P O, Creuzot-Garcher C, Solary E. Differential mechanisms of conjunctival cell death induction by ultraviolet irradiation and benzalkonium chloride. Invest Ophthalmol Vis Sci. 2006; 47: 4221–4230
   PubMed Web of Science ®Google Scholar
• Diebold Y, Calonge M, Enríquez de Salamanca A, et al. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest Ophthalmol Vis Sci. 2003; 44: 4263–4274
   PubMed Web of Science ®Google Scholar
• Diebold Y, Jarrín M, Sáez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials. 2007; 28: 1553–1564
   PubMed Web of Science ®Google Scholar
• Plantin-Carrenard E, Bringuier A, Derappe C, et al. A fluorescence microplate assay using Yopro-1 to measure apoptosis: Application to HL60 cells subjected to oxidative stress. Cell Biol Toxicol 2003; 19: 121–133
   PubMed Web of Science ®Google Scholar
• Borenfreund E, Puerner J. A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/NR-90). J Tissue Cult Methods. 1984; 9: 7–9
   Google Scholar
• Budd S L, Castilho R F, Nicholls D G. Mitochondrial membrane potential and hydroethidine-monitored superoxide generation in cultured cerebellar granule cells. FEBS Lett 1997; 415: 21–24
   PubMed Web of Science ®Google Scholar
• Idziorek T, Estaquier J, De Bels F, Ameisen J C. Yopro-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. J Immunol Methods 1995; 185: 249–258
   PubMed Web of Science ®Google Scholar
• Choucroun P, Gillet D, Dorange G, Sawicki B, Dewitte J D. Comet assay and early apoptosis. Mutat Res 2001; 478: 89–96
   PubMed Web of Science ®Google Scholar
• Dutot M, Pouzaud F, Larosche I, Brignole-Baudouin F, Warnet J M, Rat P. Fluoroquinolone eye drop-induced cytotoxicity: Role of preservative in P2X7 cell death receptor activation and apoptosis. Invest Ophthalmol Vis Sci. 2006; 47: 2812–2819
   PubMed Web of Science ®Google Scholar
• Suh B C, Kim J S, Namgung U, Ha H, Kim K T. P2X7 nucleotide receptor mediation of membrane pore formation and superoxide generation in human promyelocytes and neutrophils. J Immunol. 2001; 166: 6754–6763
   PubMed Web of Science ®Google Scholar
• Gibbons S J, Washburn K B, Talamo B R. P2X(7) receptors in rat parotid acinar cells: Formation of large pores. J Auton Pharmacol. 2001; 21: 181–190
   Google Scholar
• Eckstein L A, Van Quill K R, Bui S K, Uusitalo M S, O'Brien J M. Cyclosporin A inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci. 2005; 46: 782–790
   PubMed Web of Science ®Google Scholar
• Nicoletti I, Migliorati G, Pagliacci M C, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991; 139: 271–279
   PubMed Web of Science ®Google Scholar
• Ishida N, Odani-Kawabata N, Shimazaki A, Hara H. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 2006; 24: 1–10
   PubMed Web of Science ®Google Scholar
• Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F(2α) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003; 26: 1691–1695
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006; 47: 3395–3399
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007; 91: 673–676
   PubMed Web of Science ®Google Scholar
• Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP-receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004; 78: 767–776
   PubMed Web of Science ®Google Scholar
• Baudouin C. Allergic reaction to topical eye drops. Curr Opin Allergy Clin Immunol. 2005; 5: 459–463
   PubMed Web of Science ®Google Scholar
• Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101: 454–460
   PubMed Web of Science ®Google Scholar
• Fisher A A. Allergic contact dermatitis and conjunctivitis from benzalkonium chloride. Cutis 1987; 39: 381–383
   PubMed Web of Science ®Google Scholar
• Sherwood M B, Grierson I, Millar L, Hitchings R A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96: 327–335
   PubMed Web of Science ®Google Scholar
• Baudouin C, Pisella P J, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies. Ophthalmology. 1999; 106: 556–563
   PubMed Web of Science ®Google Scholar
• Brignole F, De Saint-Jean M, Goldschild M, Becquet F, Goguel A, Baudouin C. Expression of Fas-Fas ligand antigens and apoptotic marker APO-2.7 by the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory ocular surface disorders. Exp Eye Res 1998; 67: 687–697
   PubMed Web of Science ®Google Scholar
• Mietz H, Niesen U, Krieglstein G K. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994; 232: 561–565
   PubMed Web of Science ®Google Scholar
• De Saint Jean M, Brignole F, Feldmann G, Goguel A, Baudouin C. Interferon-gamma induces apoptosis and expression of inflammation-related proteins in Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999; 40: 2199–2212
   Web of Science ®Google Scholar
• Lavappa K S. Survey of ATCC stocks of human cell lines for HeLa contamination. In Vitro. 1978; 14: 469–475
   PubMedGoogle Scholar
• Baudouin C, Riancho L, Warnet J M, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007; 48: 4123–4128
   PubMed Web of Science ®Google Scholar
• Augustin A J, Spitznas M, Kaviani N, et al. Oxidative reactions in the tear fluid of patients suffering from dry eyes. Graefes Arch Clin Exp Ophthalmol. 1995; 233: 694–698
   PubMed Web of Science ®Google Scholar
• Ferreira S M, Lerner S F, Brunzini R, Evelson P A, Llesuy S F. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol. 2004; 137: 62–69
   PubMed Web of Science ®Google Scholar
• Izzotti A, Bagnis A, Saccà S C. The role of oxidative stress in glaucoma. Mutat Res. 2006; 612: 105–114
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007; 17: 341–349
   PubMed Web of Science ®Google Scholar
• Champeau E J, Edelhauser H F. Effect of ophthalmic preservatives on the ocular surface: Conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. The Preocular Tear Film, F J Holly. Dry Eye Institute, Inc., Lubbock, TX 1986, Vol. Chapter 27
   Google Scholar